Company intelligence / Profile preview

Leadiant Biosciences

Ownership: Private
Employees: ~1900
Development stage: Commercial

Overview

Leadiant Biosciences develops and commercializes therapies for patients with rare and ultra‐rare diseases. Its legacy includes the development of L-carnitine as a life-saving therapy for carnitine deficiency syndromes. The company currently markets products such as Carnitor® (levocarnitine) and Matulane® (procarbazine hydrochloride) in the United States. It has a global presence with roots dating back to its founding as Sigma-Tau in Italy in the late 1950s.[2][3][4][5]

Therapeutic areas: Metabolic DisordersOncology
Modalities: Small molecules[5] (e.g., levocarnitine/Carnitor, procarbazine/Matulane) *Note*: No evidence of biologics or advanced modalities in public pipeline.
Industry: Biotech

Drug pipeline

9 assets

procarbazine

Approved

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Leadiant Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leadiant Biosciences.

Explore the full profile